Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:50 am
Author: Getaka|Social: XLinkedIn

Torrent Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹3,226.17Overvalued by 21.52%vs CMP ₹4,111.00

P/E (60.4) × ROE (26.5%) × BV (₹250.00) × DY (0.78%)

₹1,456.72Overvalued by 64.57%vs CMP ₹4,111.00
MoS: -182.2% (Negative)Confidence: 63/100 (Moderate)Models: 1 Fair, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹3,997.8422%Fair (-2.8%)
Graham NumberEarnings₹614.4516%Over (-85.1%)
Earnings PowerEarnings₹317.9413%Over (-92.3%)
DCFCash Flow₹1,563.5111%Over (-62%)
Net Asset ValueAssets₹249.627%Over (-93.9%)
EV/EBITDAEnterprise₹1,250.869%Over (-69.6%)
Earnings YieldEarnings₹671.207%Over (-83.7%)
ROCE CapitalReturns₹567.769%Over (-86.2%)
Revenue MultipleRevenue₹510.365%Over (-87.6%)
Consensus (9 models)₹1,456.72100%Overvalued
Key Drivers: Wide model spread (₹250–₹3,998) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 23.9%

*Investments are subject to market risks

Investment Snapshot

69
Torrent Pharmaceuticals Ltd scores 69/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health83/100 · Strong
ROCE 27.0% ExcellentROE 26.5% ExcellentD/E 0.82 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money65/100 · Strong
FII holding stable No changeDII holding up 0.80% MF buyingPromoter holding at 68.3% Stable
Earnings Quality50/100 · Moderate
OPM stable around 32% Steady
Quarterly Momentum68/100 · Strong
Revenue (4Q): +13% YoY GrowingProfit (4Q): +22% YoY Positive
Industry Rank75/100 · Strong
P/E 60.4 vs industry 53.8 In-lineROCE 27.0% vs industry 16.4% Above peersROE 26.5% vs industry 15.2% Above peers3Y sales CAGR: 11% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Torrent Pharmaceuticals Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
0/100
Low
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 60.4 vs Ind 53.8 | ROCE 27.0% | ROE 26.5% | CFO/NP N/A
Balance Sheet Stress
10/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.82x | IntCov 0.0x | Current 1.13x | Borrow/Reserve 0.34x
Cash Flow Reliability
14/100
Weak
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹1,911 Cr | CFO/NP N/A
Ownership Accumulation
0
Neutral
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII +0.21 pp | DII -0.12 pp | Prom 0.00 pp
Business Momentum
+9
Stable
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales +0.0% | Q NP +7.4% | Q OPM 0.0 pp
Derived FieldValueHow it is derived
Valuation Gap %-64.6%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves0.34xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII Change+0.21 ppLatest FII% minus previous FII%
DII Change-0.12 ppLatest DII% minus previous DII%
Promoter Change0.00 ppLatest promoter% minus previous promoter%
Shareholder Count Change-2,012Latest shareholder count minus previous count
Quarterly Sales Change+0.0%Latest quarter sales vs previous quarter sales
Quarterly Profit Change+7.4%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change0.0 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:50 am

Market Cap 1,39,145 Cr.
Current Price 4,111
Intrinsic Value₹1,456.72
High / Low 4,483/3,101
Stock P/E60.4
Book Value 250
Dividend Yield0.78 %
ROCE27.0 %
ROE26.5 %
Face Value 5.00
PEG Ratio2.53

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Torrent Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Torrent Pharmaceuticals Ltd 1,39,145 Cr. 4,111 4,483/3,10160.4 2500.78 %27.0 %26.5 % 5.00
Lupin Ltd 1,04,004 Cr. 2,275 2,378/1,77420.9 4300.53 %21.3 %20.6 % 2.00
Dr Reddys Laboratories Ltd 1,00,960 Cr. 1,210 1,380/1,02018.1 4320.66 %22.7 %18.0 % 1.00
Cipla Ltd 96,603 Cr. 1,196 1,673/1,19420.3 4081.09 %22.7 %17.8 % 2.00
Mankind Pharma Ltd 82,619 Cr. 2,001 2,727/1,91046.8 3760.05 %15.0 %13.9 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Torrent Pharmaceuticals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 2,4912,4912,5912,6602,7322,7452,8592,8892,8092,9593,1783,3023,303
Expenses 1,7671,7641,8001,8351,8631,8621,9551,9501,8951,9952,1462,2192,215
Operating Profit 7247277918258698839049399149641,0321,0831,088
OPM % 29%29%31%31%32%32%32%32%33%33%32%33%33%
Other Income -1093426553124-1633-42-37-40-23
Interest 10210710391808075645756564845
Depreciation 193196191201213203197198199201201204206
Profit before tax 419433531559631631656661691665738791814
Tax % 30%34%29%31%30%29%30%31%27%25%26%25%22%
Net Profit 292287378386443449457453503498548591635
EPS in Rs 8.638.4811.1711.4113.0913.2713.5013.3814.8614.7116.1917.4618.76

Last Updated: March 3, 2026, 2:10 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 5:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 4,1724,6366,6875,8165,9507,6737,9398,0058,5089,62010,72811,51612,742
Expenses 3,2163,6163,9544,4384,6015,6905,7695,5246,0776,7787,3607,7958,575
Operating Profit 9551,0202,7331,3771,3491,9832,1702,4802,4312,8423,3683,7214,167
OPM % 23%22%41%24%23%26%27%31%29%30%31%32%33%
Other Income 3428632223299-30012157-28845146-1-142
Interest 59175184206308504451353255333354252205
Depreciation 87191238307409618654658662707808795812
Profit before tax 8449402,3431,0889315621,1871,5261,2261,8472,3522,6733,008
Tax % 21%20%26%14%27%22%14%18%37%33%30%28%
Net Profit 6647511,7339346784361,0251,2527771,2451,6561,9112,272
EPS in Rs 19.6222.1951.2227.5920.0412.8930.2836.9922.9736.7948.9456.4767.12
Dividend Payout % 25%25%34%25%35%66%53%47%105%60%57%57%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)13.10%130.76%-46.11%-27.41%-35.69%135.09%22.15%-37.94%60.23%33.01%15.40%
Change in YoY Net Profit Growth (%)0.00%117.66%-176.86%18.70%-8.28%170.78%-112.95%-60.09%98.17%-27.22%-17.61%

Torrent Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:10%
5 Years:8%
3 Years:11%
TTM:8%
Compounded Profit Growth
10 Years:10%
5 Years:14%
3 Years:21%
TTM:21%
Stock Price CAGR
10 Years:17%
5 Years:21%
3 Years:34%
1 Year:5%
Return on Equity
10 Years:23%
5 Years:23%
3 Years:24%
Last Year:27%

Last Updated: September 5, 2025, 1:46 pm

Balance Sheet

Last Updated: December 4, 2025, 2:07 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 858585858585858585169169169169
Reserves 1,8182,4063,4094,2664,5384,6404,7395,7535,8686,0296,6877,4218,280
Borrowings 1,1322,7402,3522,5106,4626,0385,7844,8744,0705,3694,0223,2022,822
Other Liabilities 1,9882,5893,0402,7403,1593,3513,4023,3632,8843,0433,6273,6034,244
Total Liabilities 5,0227,8208,8869,60114,24314,11314,01014,07512,90614,61014,50514,39615,515
Fixed Assets 8752,8332,8593,6887,8557,7487,5337,0656,4238,1218,1387,9477,841
CWIP 5346781,042519647617712889630765361478488
Investments 1862987808044923532181226199173156133
Other Assets 3,4274,0114,2064,5895,2495,3955,7635,9405,6285,5245,8345,8157,053
Total Assets 5,0227,8208,8869,60114,24314,11314,01014,07512,90614,61014,50514,39615,515

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 5998102,7421,0098941,7981,3932,0051,8032,3683,2662,585
Cash from Investing Activity + -418-2,113-869-798-4,677-246229-444-196-2,335-160-549
Cash from Financing Activity + 861,212-1,435-1933,417-1,314-1,549-1,651-1,78177-2,780-2,298
Net Cash Flow 268-9043718-36623873-89-174110327-262
Free Cash Flow 2015742,1505231051,1389901,6711,6071,9532,9671,991
CFO/OP 90%85%121%101%87%105%77%88%91%97%112%86%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow954.00-1.000.00-1.00-5.00-5.00-3.00-2.00-2.00-3.00-1.000.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 9612579607768766970746359
Inventory Days 297275314318429318362456368298310334
Days Payable 421472523356447345345351250224284239
Cash Conversion Cycle -28-71-1302159429317418814789154
Working Capital Days 2429-128-80-62-52-57-33-277
ROCE %35%27%48%19%13%13%15%17%19%20%23%27%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 71.25%71.25%71.25%71.25%71.25%71.25%71.25%68.31%68.31%68.31%68.31%68.31%
FIIs 12.04%12.85%13.15%14.08%14.14%14.22%14.46%16.17%16.31%16.09%15.92%16.13%
DIIs 8.89%8.22%7.91%7.11%7.15%7.17%6.98%8.25%8.25%8.54%9.17%9.05%
Government 0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%
Public 7.71%7.59%7.59%7.46%7.34%7.25%7.21%7.17%7.02%6.93%6.47%6.41%
No. of Shareholders 63,83161,57269,61269,11771,15474,76579,84885,03586,00581,85678,22676,214

Shareholding Pattern Chart

No. of Shareholders

Torrent Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Large Cap Fund 3,180,904 3.44 1378.38N/AN/AN/A
Axis Large Cap Fund 964,751 1.29 418.06911,3972026-02-23 03:26:155.85%
UTI Flexi Cap Fund 662,000 1.25 286.86686,0002026-03-12 01:55:10-3.5%
Franklin India Large Cap Fund 582,022 3.33 252.21777,8622026-03-24 02:01:05-25.18%
Canara Robeco Large Cap Fund 407,164 1.03 176.44N/AN/AN/A
SBI Healthcare Opportunities Fund 400,000 4.25 173.33N/AN/AN/A
Axis Large & Mid Cap Fund 387,176 1.08 167.78N/AN/AN/A
Axis ELSS Tax Saver Fund 337,092 0.44 146.07330,9302026-02-23 02:15:051.86%
HDFC Large and Mid Cap Fund 336,766 0.51 145.93N/AN/AN/A
Nippon India Value Fund 328,626 1.58 142.4353,6262025-11-03 03:03:49-7.07%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 5.005.005.005.005.00
Basic EPS (Rs.) 56.4748.9436.7945.9373.98
Diluted EPS (Rs.) 56.4748.9436.7945.9373.98
Cash EPS (Rs.) 79.9672.8257.6785.05112.84
Book Value[Excl.RevalReserv]/Share (Rs.) 224.27202.57183.13351.75344.90
Book Value[Incl.RevalReserv]/Share (Rs.) 224.27202.57183.13351.75344.90
Revenue From Operations / Share (Rs.) 340.25316.96284.23502.72472.97
PBDIT / Share (Rs.) 110.63101.2185.30155.27149.90
PBIT / Share (Rs.) 87.1477.3364.43116.15111.04
PBT / Share (Rs.) 78.9769.4954.5872.4490.18
Net Profit / Share (Rs.) 56.4748.9436.7945.9273.97
NP After MI And SOA / Share (Rs.) 56.4748.9436.7945.9273.97
PBDIT Margin (%) 32.5131.9330.0130.8831.69
PBIT Margin (%) 25.6124.3922.6623.1023.47
PBT Margin (%) 23.2021.9219.2014.4019.06
Net Profit Margin (%) 16.5915.4412.949.1315.63
NP After MI And SOA Margin (%) 16.5915.4412.949.1315.63
Return on Networth / Equity (%) 25.1724.1520.0913.0521.44
Return on Capital Employeed (%) 28.7127.1622.7922.6320.46
Return On Assets (%) 12.7510.998.295.938.89
Long Term Debt / Equity (X) 0.150.230.400.350.50
Total Debt / Equity (X) 0.390.570.850.670.82
Asset Turnover Ratio (%) 0.760.710.680.530.50
Current Ratio (X) 1.191.030.971.201.13
Quick Ratio (X) 0.650.610.560.640.58
Inventory Turnover Ratio (X) 4.780.730.630.680.69
Dividend Payout Ratio (NP) (%) 56.6661.2969.3087.0927.03
Dividend Payout Ratio (CP) (%) 40.0241.1944.2147.0217.72
Earning Retention Ratio (%) 43.3438.7130.7012.9172.97
Cash Earning Retention Ratio (%) 59.9858.8155.7952.9882.28
Interest Coverage Ratio (X) 14.849.698.6610.307.19
Interest Coverage Ratio (Post Tax) (X) 8.675.434.735.954.55
Enterprise Value (Cr.) 111924.9091136.9056758.9950939.2747229.23
EV / Net Operating Revenue (X) 9.728.505.905.995.90
EV / EBITDA (X) 29.8926.6019.6619.3818.62
MarketCap / Net Operating Revenue (X) 9.518.215.415.565.37
Retention Ratios (%) 43.3338.7030.6912.9072.96
Price / BV (X) 14.4212.848.397.957.37
Price / Net Operating Revenue (X) 9.518.215.415.565.37
EarningsYield 0.010.010.020.010.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Torrent Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 15/07/1972 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1972PLC002126 and registration number is 002126. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 9682.44 Cr. and Equity Capital is Rs. 169.23 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsTorrent House, Off Ashram Road, Ahmedabad Gujarat 380009Contact not found
Management
NamePosition Held
Mr. Sudhir MehtaChairman Emeritus
Mr. Samir MehtaExecutive Chairman
Mr. Aman Samir MehtaWhole Time Director
Mr. Jinal MehtaNon Executive Director
Mr. Manish Mahendra ChoksiIndependent Director
Mr. Nikhil KhattauIndependent Director
Ms. Ameera ShahIndependent Director
Ms. Nayantara BaliIndependent Director

FAQ

What is the intrinsic value of Torrent Pharmaceuticals Ltd and is it undervalued?

As of 05 April 2026, Torrent Pharmaceuticals Ltd's intrinsic value is ₹1456.72, which is 64.57% lower than the current market price of ₹4,111.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (26.5 %), book value (₹250), dividend yield (0.78 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Torrent Pharmaceuticals Ltd?

Torrent Pharmaceuticals Ltd is trading at ₹4,111.00 as of 05 April 2026, with a FY2026-2027 high of ₹4,483 and low of ₹3,101. The stock is currently in the middle of its 52-week range. Market cap stands at ₹1,39,145 Cr..

How does Torrent Pharmaceuticals Ltd's P/E ratio compare to its industry?

Torrent Pharmaceuticals Ltd has a P/E ratio of 60.4, which is above the industry average of 53.84. The premium over industry average may reflect growth expectations or speculative interest.

Is Torrent Pharmaceuticals Ltd financially healthy?

Key indicators for Torrent Pharmaceuticals Ltd: ROCE of 27.0 % indicates efficient capital utilization; ROE of 26.5 % shows strong shareholder returns. Dividend yield is 0.78 %.

Is Torrent Pharmaceuticals Ltd profitable and how is the profit trend?

Torrent Pharmaceuticals Ltd reported a net profit of ₹1,911 Cr in Mar 2025 on revenue of ₹11,516 Cr. Compared to ₹777 Cr in Mar 2022, the net profit shows an improving trend.

Does Torrent Pharmaceuticals Ltd pay dividends?

Torrent Pharmaceuticals Ltd has a dividend yield of 0.78 % at the current price of ₹4,111.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Torrent Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports